MedTrace Logo

Anatomic Outcomes Following Ozurdex Injections

NCT01282411 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2016-07-27

No results posted yet for this study

Summary

Ozurdex(TM) has recently been FDA approved for use in macular edema secondary to retinal vein occlusion. It remains unclear how quickly the drug works and for how long as the initial studies did not have frequent anatomic monitoring. This study will utilize frequent Spectral domain OCT imaging to better understand the onset of treatment effectiveness and duration of action on the anatomic thickness of the retina, in addition to distinguishing structural abnormalities of responders from non-responders.

Conditions

  • Retinal Vein Occlusions

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Barnes Retina Institute

    lead OTHER

Principal Investigators

  • Gaurav K Shah, MD · Barnes Retina Institute

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-05-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01282411 on ClinicalTrials.gov